Compounds > act-335827
Page last updated: 2024-11-13

act-335827

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID54765113
CHEMBL ID2413367
SCHEMBL ID198063
MeSH IDM0590717

Synonyms (17)

Synonym
bdbm50438822
chembl2413367 ,
SCHEMBL198063
1354039-86-3
act 335827
(ar,1s)-1-[(3,4-dimethoxyphenyl)methyl]-3,4-dihydro-6,7-dimethoxy-n-(1-methylethyl)-a-phenyl-2(1h)-isoquinolineacetamide
AKOS024458449
act-335827
gtpl9122
(2r)-2-[(1s)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-2-phenyl-n-propan-2-ylacetamide
compound 9 [pmid: 23589487]
HY-108683
(2r)-2-[(1s)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl]-n-isopropyl-2-phenyl-acetamide
Q27074308
(r)-2-((s)-1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-3,4-dihydroisoquinolin-2(1h)-yl)-n-isopropyl-2-phenylacetamide
DTXSID901336764
CS-0029474
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Orexin receptor type 1Homo sapiens (human)IC50 (µMol)0.00600.00600.04450.1990AID1237020; AID765089; AID767538
Orexin receptor type 1Homo sapiens (human)Ki0.00600.00030.28763.1623AID1725492
Orexin receptor type 2Homo sapiens (human)IC50 (µMol)0.41700.00040.51858.1000AID1237021; AID765090; AID767536
Orexin receptor type 2Homo sapiens (human)Ki0.41700.00020.37713.7810AID1328716; AID1725493
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)0.41700.00030.55704.2000AID765090
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
neuropeptide signaling pathwayOrexin receptor type 1Homo sapiens (human)
chemical synaptic transmissionOrexin receptor type 1Homo sapiens (human)
feeding behaviorOrexin receptor type 1Homo sapiens (human)
regulation of cytosolic calcium ion concentrationOrexin receptor type 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeOrexin receptor type 1Homo sapiens (human)
cellular response to hormone stimulusOrexin receptor type 1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayOrexin receptor type 2Homo sapiens (human)
neuropeptide signaling pathwayOrexin receptor type 2Homo sapiens (human)
chemical synaptic transmissionOrexin receptor type 2Homo sapiens (human)
feeding behaviorOrexin receptor type 2Homo sapiens (human)
regulation of circadian sleep/wake cycle, wakefulnessOrexin receptor type 2Homo sapiens (human)
circadian sleep/wake cycle processOrexin receptor type 2Homo sapiens (human)
locomotionOrexin receptor type 2Homo sapiens (human)
regulation of cytosolic calcium ion concentrationOrexin receptor type 2Homo sapiens (human)
cellular response to hormone stimulusOrexin receptor type 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
G protein-coupled receptor activityOrexin receptor type 1Homo sapiens (human)
protein bindingOrexin receptor type 1Homo sapiens (human)
orexin receptor activityOrexin receptor type 1Homo sapiens (human)
peptide hormone bindingOrexin receptor type 1Homo sapiens (human)
peptide bindingOrexin receptor type 1Homo sapiens (human)
protein bindingOrexin receptor type 2Homo sapiens (human)
neuropeptide receptor activityOrexin receptor type 2Homo sapiens (human)
orexin receptor activityOrexin receptor type 2Homo sapiens (human)
peptide hormone bindingOrexin receptor type 2Homo sapiens (human)
peptide bindingOrexin receptor type 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneOrexin receptor type 1Homo sapiens (human)
synapseOrexin receptor type 1Homo sapiens (human)
plasma membraneOrexin receptor type 1Homo sapiens (human)
plasma membraneOrexin receptor type 2Homo sapiens (human)
synapseOrexin receptor type 2Homo sapiens (human)
plasma membraneOrexin receptor type 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID765090Binding affinity to orexin receptor 2 (unknown origin)2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Selective orexin receptor antagonists.
AID1328715Displacement of (2S)-N-(2-phenylphenyl)-1-[2-[1-(tritritiomethyl)benzimidazol-2-yl]sulfanylacetyl]pyrrolidine-2-carboxamide from human OX1 receptor Ile408-Val mutant expressed on CHO cell membrane measured after 3 hrs by TopCount method2016Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23
Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology.
AID1725493Binding affinity to human OX2R2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Substituted Azabicyclo[2.2.1]heptanes as Selective Orexin-1 Antagonists: Discovery of JNJ-54717793.
AID1237021Antagonist activity at orexin-2 receptor (unknown origin)2015Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15
Recent trends in orexin research--2010 to 2015.
AID1237020Antagonist activity at orexin-1 receptor (unknown origin)2015Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15
Recent trends in orexin research--2010 to 2015.
AID767538Antagonist activity at OX1 receptor (unknown origin)2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Substituted tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor.
AID767536Antagonist activity at OX2 receptor (unknown origin)2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Substituted tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor.
AID1328716Displacement of (2S)-N-(2-pyrrol-1-ylphenyl)-1-[2-[1-(tritritiomethyl)benzimidazol-2-yl]sulfanylacetyl]pyrrolidine-2-carboxamide from human OX2 receptor expressed on CHO cell membrane measured after 3 hrs by TopCount method2016Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23
Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology.
AID765089Binding affinity to orexin receptor 1 (unknown origin)2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Selective orexin receptor antagonists.
AID1328717Selectivity index, ratio of Ki for human OX2 receptor expressed on CHO cell membrane to Ki for Ile408-Val variant human OX1 receptor expressed on CHO cell membrane2016Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23
Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology.
AID1725492Binding affinity to human OXIR2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Substituted Azabicyclo[2.2.1]heptanes as Selective Orexin-1 Antagonists: Discovery of JNJ-54717793.
AID1346418Human OX2 receptor (Orexin receptors)2013ChemMedChem, Jun, Volume: 8, Issue:6
Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist.
AID1346381Human OX1 receptor (Orexin receptors)2013ChemMedChem, Jun, Volume: 8, Issue:6
Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist.
AID1346333Rat OX2 receptor (Orexin receptors)2013ChemMedChem, Jun, Volume: 8, Issue:6
Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist.
AID1346327Rat OX1 receptor (Orexin receptors)2013ChemMedChem, Jun, Volume: 8, Issue:6
Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (33.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
sb 408124
SB 408124: a hypocretin receptor type 1 (HcrtR1) antagonist		3.1810organohalogen compound;
quinolines
sb 334867-a
1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea: selective OX1 receptor antagonist		2.5820naphthyridine derivative
jnj 10397049
JNJ 10397049: a selective orexin receptor-2 antagonist		3.1810
sb674042
SB674042: nonpeptide antagonist to the human orexin-1 receptor; structure in first source		3.1810
tcs ox2 29
[no description available]		3.1810
almorexant
almorexant: a dual orexin receptor antagonist for treatment of insomnia		3.5920isoquinolines
suvorexant
suvorexant: an orexin receptor antagonist; structure in first source. suvorexant : An aromatic amide obtained by formal condensation of the carboxy group of 5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid with the secondary amino group of 5-chloro-2-[(5R)-5-methyl-1,4-diazepan-1-yl]-1,3-benzoxazole. An orexin receptor antagonist used for the management of insomnia.		4.11201,3-benzoxazoles;
aromatic amide;
diazepine;
organochlorine compound;
triazoles		central nervous system depressant;
orexin receptor antagonist
mk-6096
MK-6096: antagonist of orexin receptors 1 and 2; structure in first source		4.1120
sb 649868
N-((1-((5-(4-fluorophenyl)-2-methyl-4-thiazolyl)carbonyl)-2-piperidinyl)methyl)-4-benzofurancarboxamide: antagonist of both orexin 1 and orexin 2 receptors; for treating insomnia; structure in first source		3.1810
act-462206
ACT-462206: an antagonist of both orexin 1 and oxexin 2 receptors; structure in first source		3.2110
gsk 1059865
[no description available]		3.1810
orexin-a
[no description available]		2.0810
ConditionIndicatedRelationship StrengthStudiesTrials
Long Sleeper Syndrome
[description not available]		03.0310
Anxiety
Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.		03.0310
Sleep Wake Disorders
Abnormal sleep-wake schedule or pattern associated with the CIRCADIAN RHYTHM which affect the length, timing, and/or rigidity of the sleep-wake cycle relative to the day-night cycle.		03.0310